Momordica

Momordica (Momordica charantia L.)

1. Identity: Botanical Classification, Names, and Common Forms

Momordica charantia L. (M. charantia), a member of the Cucurbitaceae family, is widely distributed in tropical and subtropical regions of the world. Its name derives from the Latin verb momordi (to bite), referring to the leaves, which look to have been bitten, and from the Greek noun chárax, meaning "support cane," for its use as a climber in pergolas. Momordica charantia is an herbal climber grown in tropical and subtropical regions, belonging to the Cucurbitaceae family.

The plant is known by a large number of common names depending on the region. Common synonyms and trade names include balsam apple, balsam pear, bitter apple, bitter cucumber, bitter gourd, karela, lakwa, margose, and wild cucumber. Additional alternate names include balsam pear, carilla, cerasee, cundeamor, goo-fah, and karela. In South Asian contexts it is most widely called karela; in East Asian contexts it is often called kugua.

Morphologically, the bitter melon is an herbaceous vine which bears tendrils and creeps along supports. Leaves are simple and alternate, and flowers are yellow. Male and female flowers grow on separate plants. The fruit of the plant has an oblong shape with a warty exterior and is dark green in color. As the fruit ripens, the flesh (rind) becomes slightly tougher and bitterer. On the other hand, the pith becomes sweet and intensely red; it can be eaten uncooked in this state, and is a popular part in some Southeast Asian salads.

Common Preparations and Forms

• The most popular ethnomedicinal preparations of the bitter gourd include karela juice, which is obtained by crushing and straining the fruit.
• Dried fruit powder, encapsulated or tableted for use as a dietary supplement.
• Its utilization in the form of value-added or therapeutic products like tonic, emetic, and laxative is well reported in India and Sri Lanka.
• Supplement capsules used in clinical studies have contained formulations such as 500 mg capsules, each containing 200 mg Momordica extract (standardized to 2.5% bitter principle) and 300 mg dried fruit powder.
• Aqueous, ethanolic, and ether extracts are used in research and traditional preparations, and the plant's roots, leaves, seeds, and fruits are all used medicinally.

2. Traditional and Historical Use

The combination of medicine and vegetable usage has made Momordica charantia popular for thousands of years. Apart from its culinary use, M. charantia has a long history in traditional medicine, serving as stomachic, laxative, or anthelmintic, and, most notably, for the treatment of diabetes and its complications.

Asian Traditions

M. charantia has been used since ancient times in Traditional Chinese Medicine for treating high blood sugar and early signs of diabetes. In Ayurveda medicine, bitter melon, known as karela, has been used for thousands of years. It has been used in various Asian traditional medicines for the treatment of cholera, bronchitis, anemia, blood diseases, ulcer, diarrhea, dysentery, gonorrhea, rheumatism, gout, worms, colic, disease of liver and spleen, cancer, and diabetes.

Ayurvedic Use

It is a tropical and subtropical vine and its use in the Ayurvedic system as alternative medicine is well recognized. According to Ayurveda, roots are useful in the treatment of eye-related diseases.

Caribbean and Latin American Traditions

In the Caribbean traditional medicine, leaf juice is used to treat hypertension, malaria, worm infections, and womb infections. Developing countries such as Brazil, China, Colombia, Cuba, Ghana, and India have used it traditionally as a treatment for diabetes. In New York City, Momordica charantia can be found cultivated in community gardens in Caribbean and Latino or Hispanic neighborhoods, and the species is also sold in Botánica shops.

West African Traditions

The importance of Momordica charantia in ritual use in Togo reinforces its importance as a medicinal plant for which there is strong consensus for use in treatment of viral infections and gastrointestinal conditions. The bioassay data suggest that these uses have a pharmacological basis.

Breadth of Recorded Traditional Indications

The popularity of Momordica charantia in various systems of traditional medicine covers a broad range of ailments including antidiabetic, abortifacient, anthelmintic, contraceptive, dysmenorrhea, eczema, emmenagogue, antimalarial, galactagogue, gout, jaundice, abdominal pain, kidney stone, laxative, leprosy, leucorrhea, piles, pneumonia, psoriasis, purgative, rheumatism, fever, and scabies.

3. Key Constituents and Active Compounds

Phytochemicals including proteins, polysaccharides, flavonoids, triterpenes, saponins, ascorbic acid, and steroids have been found in this plant. Momordica is a good source of bioactive constituents such as saponins, flavonoids, triterpenoids, alkaloids, polysaccharides, steroids, coumarins, and mucilage.

Major Identified Bioactive Compounds

• Charantin: The first report of a possible antidiabetic principle mentioned a mixture of the two phytosterol glycosides β-sitosterol 3-O-β-D-glucoside and 5,22-stigmasterol 3-O-β-D-glucoside, which was named charantin. Charantin is a steroidal saponin agent with insulin-like properties.
• Polypeptide-P (plant insulin / p-insulin): Polypeptide-P was described as an 11 kDa polypeptide similar to bovine insulin, as a possible antidiabetic principle. Polypeptide-P, isolated from the fruits and seeds of M. charantia, showed a potent hypoglycemic effect when administered subcutaneously to gerbils and humans.
• Momordicin (I and II): The methanol extract of M. charantia contains various cucurbitane-type triterpenoids, which are mainly responsible for its pharmacological effects. Among these, momordicine I and II are particularly known for their bioactivity. Momordicin is an alkaloid responsible for the bitterness of the fruit.
• Vicine: The pyrimidine nucleoside vicine was isolated from the seeds, and administration of a dose equivalent to 16 g of seeds per kg body weight caused hypoglycemia in rats.
• Cucurbitane-type triterpenes: A new cucurbitane-type triterpene glycoside taiwacin A, a new 23,24,25,26,27-pentanorcucurbitane taiwacin B, and a known cucurbitane-type triterpene glycoside and a known steroid glycoside were isolated from the stems and fruits of Momordica charantia.
• Ribosome-Inactivating Proteins (RIPs) — MAP30 and α/β-Momorcharins: It has been reported that RIPs are members of the single chain ribosome inactivating protein (SCRIP) family which act irreversibly on ribosomes by removing adenine residues from eukaryotic ribosomal RNA. Alpha-momorcharin (α-MMC) and Momordica anti-HIV protein (MAP30) from Momordica charantia L. have been confirmed to possess anti-tumor and anti-virus activities.
• Flavonoids and phenolic compounds: The major compounds isolated from bitter melon and identified as hypoglycemic agents include polysaccharides; proteins and peptides such as polypeptide-p and peroxidase; saponins and terpenoids such as charantin; and flavonoids and phenolic compounds such as quercetin, rutin, kaempferol, and isorhamnetin.
• Additional isolated compounds: Several compounds including charantin, momorcharin, charine, cryptoxanthin, diosgenin, gentisic acid, momorcharasides, momordenol, momordicilin, momordicin, momordicinin, momordin, momordicosides, polypeptide-p, rosmarinic acid, taraxerol, trehalose, vicine, and zeaxanthin have been isolated from this plant.

4. Established Mechanisms of Action

Antidiabetic / Hypoglycemic Mechanisms

Proposed mechanisms include improved histological architecture of the islets of Langerhans and beta-cell regeneration, insulin secretagogue activity, enhanced peripheral glucose utilization, inhibition of glucose-6-phosphatase and fructose biphosphatase glucogenic enzymes, and increases in peroxisome proliferator-activated receptor gamma (PPAR-γ) activity with decreases in protein Kinase C (PKC-β) activity in kidneys.

Active phytoconstituents including charantin, vicine, and polypeptide-P are thought to alter hepatic glucose metabolism and stimulate insulin secretion. Aqueous extract of immature fruits of M. charantia has been shown to partially stimulate insulin release from isolated β-cells of obese-hyperglycemic mice.

Momordicine I exerts an antidiabetic effect by modulating insulin signaling pathways, enhancing glucose uptake, and inhibiting glucose production in the liver.

Pancreatectomy was found to reduce but not abolish the hypoglycemic effect of charantin, indicating a dual mechanism of action. This suggests both pancreatic (insulin-secretory) and extrapancreatic (peripheral glucose utilization) components.

PPARγ Activation

3β,7β-dihydroxy-25-methoxycucurbita-5,23-diene-19-al (DMC), a cucurbitane-type triterpene isolated from wild bitter gourd, was found to induce apoptotic death in breast cancer cells through peroxisome proliferator-activated receptor (PPARγ) activation. Luciferase reporter assays indicated the ability of DMC to activate PPARγ, and pharmacological inhibition of PPARγ protected cells from DMC's antiproliferative effect.

Antiviral Mechanisms — Ribosome Inactivation

RIPs act irreversibly on ribosomes by removing adenine residues from eukaryotic ribosomal RNA. MAP30 possesses various biological activities such as interaction with viral-infected ribosomes to inhibit protein biosynthesis in the infected cells. Furthermore, MAP30 shows dual ability to cleave both DNA and RNA substrates.

Anti-inflammatory Mechanisms

In laboratory inflammation models using lipopolysaccharide (LPS), a potent innate immune-activating stimuli which can directly activate macrophages, activated RAW264.7 mouse macrophage cells show increased production of measurable inflammatory mediators such as leukotrienes, tumor necrosis factor-alpha (TNF-α), and interleukins. Extracts of M. charantia have been demonstrated to suppress these responses.

Antioxidant Mechanisms

Cucurbitane-type triterpene glycosides including taiwacin A and B revealed ABTS radical cation scavenging activity. The 80% ethanol extract of M. charantia fruit exhibited the most antioxidant activity in LC-MS-based metabolomics screening. The hypoglycemic properties of the plant have been attributed to momorcharin, polypeptide-p, and vicine, which generally exert insulin-like effects.

5. Scientific Evidence by Area of Use

5.1 Glycemic Control and Diabetes (Type 2 Diabetes and Pre-diabetes)

The antidiabetic activity of M. charantia is its most extensively studied pharmacological property. Evidence spans in vitro, animal, and human clinical studies, though the overall quality of human evidence remains contested.

Animal Evidence

The bitter gourd extracts have been evaluated for numerous pharmacological activities, most of which were performed on animals. Fruits and seed extracts reduced fasting glucose and glycosylated hemoglobin A1c in comparison to vehicle control when tested in animal models of type 2 diabetes.

Human Clinical Evidence — Mixed and Contested

Four clinical trials found bitter melon juice, fruit, and dried powder to have a moderate hypoglycemic effect. These studies were small and were not randomized or double-blind, however.

A 2024 systematic review and meta-analysis of randomized controlled trials reported statistically significant findings. M. charantia supplementation resulted in significant reductions in fasting blood glucose (WMD: −0.85 mmol/L; 95% CI: −1.44, −0.26; p = 0.005; I² = 73.4%), postprandial glucose (WMD: −2.28 mmol/L; 95% CI: −3.35, −1.21; p = 0.000; I² = 66.9%), glycosylated hemoglobin A1c (WMD: −0.38%; 95% CI: −0.53, −0.23; p = 0.000; I² = 37.6%), and total cholesterol (WMD: −0.38 mmol/L; 95% CI: −0.70, −0.07; p = 0.017; I² = 63.6%). However, no significant differences were observed in terms of triglyceride (TG), high-density lipoprotein (HDL), and low-density lipoprotein (LDL).

In contrast, a separate systematic review and meta-analysis reported a null finding. Nine studies were included in the meta-analysis with 414 patients in total and 4–16 weeks of follow-up. In case of the meta-analysis of change scores, no significant effect could be observed for bitter melon treatment over placebo on fasting blood glucose level (MD = −0.03; 95% CI: −0.38 to 0.31; I² = 34%), HbA1c level (MD = −0.12; 95% CI: −0.35 to 0.11; I² = 56%), HDL, LDL, total cholesterol, body weight, BMI, systolic blood pressure, or diastolic blood pressure.

Momordica treatment was not associated with a notable change in ALT, AST, and creatinine levels compared to placebo, which supports the safety of this plant. However, the power was overall low and the meta-analyzed studies were also too short to reliably detect long-term metabolic effects. This highlights the need for additional research in carefully planned clinical trials of longer duration.

A specific randomized, controlled juice trial showed that participants who received 100 ml bitter melon juice containing 140 g of bitter melon pulp 30 minutes prior to a 75-gram oral glucose tolerance test showed that the intake of 100 ml of bitter melon juice significantly reduced the 2-hour postprandial glucose by an average of 34.4 mg/dL compared with placebo juice.

A randomized controlled trial in 75 uncomplicated type 2 diabetes patients found that Group B, receiving 1.5 g of Momordica charantia along with oral anti-diabetic agents, had shown an improved glycemic profile along with insulin resistance. A reduction in total cholesterol, LDL cholesterol, and oxidative stress was shown and an increase in HDL levels. The results suggest that the add-on treatment of 1.5 g per day of Momordica charantia can be an effective treatment option for glycemic control, lowering total cholesterol, and reducing oxidative stress in type 2 diabetes mellitus patients.

One placebo-controlled cross-over trial focused on pre-diabetic subjects. This placebo-controlled cross-over trial with 2.5 g powder supplementation for 8 weeks reported a significant reduction in fasting glucose. No effects were observed on other metabolic markers such as HbA1c, insulin, or cholesterol.

Evidence strength: Despite the number of preclinical studies performed each year continuing to increase and improving understanding of M. charantia mode of action, a recent meta-analysis of five randomized clinical trials confirmed its glucose-lowering ability with only very low certainty of evidence. In the major meta-analysis, researchers observed marked inconsistent results of individual trials and established neither dose nor duration of treatment accurately. The overall body of human evidence is thus characterized as preliminary to low-certainty, with contradictory findings across trials.

5.2 Lipid Profile and Metabolic Syndrome

Several studies have shown that Momordica charantia L. has beneficial effects on metabolic syndrome parameters and exerts antidiabetic, anti-hyperlipidemic, and anti-obesity activities. However, as noted above, the 2024 systematic review found no significant change in TG, HDL, or LDL over placebo, and the effect on body weight and BMI was likewise non-significant. Evidence in this domain is preliminary, hampered by small sample sizes and short study durations.

5.3 Antiviral Activity

Increasing evidence suggests that M. charantia is a significant source of antiviral compounds that could act against many different types of viruses in humans. Several in vitro studies have confirmed that bitter melon possesses inhibitory effects against different human viruses.

MAP30 (Momordica Anti-HIV Protein), alpha- and beta-momorcharins inhibit HIV replication in acutely and chronically infected cells and thus are considered potential therapeutic agents in HIV infection and AIDS. Further, MAP30 improved the efficacy of anti-HIV therapy when used in combination with other anti-viral drugs. MAP30 holds therapeutic promise because not only is it active against infection and replication of both HSV and HIV but it is non-toxic to normal cells.

In-vitro antimicrobial and antiviral studies showed that antimicrobial assays revealed activity against Candida albicans, Escherichia coli, and Staphylococcus aureus. The extracts exhibited potent inhibition of HIV-I reverse transcriptase, with an IC50 of 0.125 mg/mL observed for the pith extract.

Evidence strength: Antiviral evidence is predominantly in vitro and preclinical. No completed human clinical trials have been identified establishing antiviral efficacy in humans. The ribosome-inactivating proteins face significant clinical development obstacles, including strong immunogenicity and short plasma half-life that limit their clinical application.

5.4 Anticancer Activity

Due to the presence of many bioactive compounds, some of which possess potent biological actions, this plant is used in folk medicine for the treatment of different pathologies, mainly diabetes, but also cancer, and other inflammation-associated diseases.

A cucurbitane-type triterpene (DMC), isolated from wild bitter gourd, induced apoptotic death in breast cancer cells through PPARγ activation. Pharmacological inhibition of PPARγ protected cells from DMC's antiproliferative effect. Western blot analysis indicated that DMC suppressed the expression of many PPARγ-targeted signaling effectors, including cyclin D1, CDK6, Bcl-2, XIAP, cyclooxygenase-2, NF-κB, and estrogen receptor α, and induced endoplasmic reticulum stress.

Studies examining the effect of momordicine I on various cancer cell lines and inflammation models have reported that it exerts cytotoxic and anti-inflammatory effects. A recent study demonstrated that momordicine I could suppress the growth of head and neck cancer by altering the immunosuppressive effects of tumor-infiltrating macrophages and B lymphocytes.

Alpha-momorcharin (α-MMC) and MAP30, two major components in M. charantia, were found to be potent inhibitors of protein synthesis due to their ribosome-specific N-glycosidase activity. Accordingly, α-MMC and MAP30 have been shown to exhibit antitumor activity in vitro and in vivo, including against lung, colon, liver, epidermis, and breast cancer.

Evidence strength: It is widely demonstrated that M. charantia extracts contribute to lowering glycemia in patients affected by type 2 diabetes. However, the majority of existing studies on M. charantia bioactive compounds were performed only on cell lines and in animal models. Therefore, because the real impact of bitter melon on human health has not been thoroughly demonstrated, systematic clinical studies are needed to establish its efficacy and safety in patients. Anticancer evidence is limited to in vitro and preclinical animal studies; no clinical trial data are available.

5.5 Anti-inflammatory Activity

Various biological activities of M. charantia have been reported, including anti-inflammatory activities. Preclinical models have been used extensively, with extracts shown to suppress macrophage activation and reduce pro-inflammatory cytokine production in cell-based experiments. Evidence is mechanistically plausible but remains at the in vitro and animal level, with no confirmatory human trials.

5.6 Antioxidant Activity

Cucurbitane-type triterpene glycosides isolated from M. charantia revealed ABTS radical cation scavenging activity and inhibitory effect on xanthine oxidase (XO) activity. Antioxidant properties have been documented in multiple in vitro assays; human evidence is limited.

5.7 Gastrointestinal and Antiulcer Activity

M. charantia has been used for gastric ulcer diseases. In animal models, oral administration of polypeptide K (PPK) at all concentrations (10, 25, and 50 mg/kg) showed significant (p < 0.05) reduction in total area of lesion in both hydrochloride ethanol- and indomethacin-induced gastric ulcer models. This evidence is animal-only; no confirmatory human trial data are available.

5.8 Reproductive and Endocrine Effects

Estrogen levels and progesterone levels in female rats were reduced in a dose-dependent manner when given aqueous leaf extracts of M. charantia. The antifertility effect is achieved in a dose-dependent manner. An animal study of male rats found that high dose of M. charantia seed extracts caused infertility in male rats. The interruption in fertility was probably attributed to direct toxicity to seminiferous tubules, epididymis, and the lowered testosterone level which might impact on sperm parameters.

In a letrozole-induced PCOS rat model, the study validates the bitter melon potential as an insulin sensitizer and ovulation enhancer and authenticates its potential in PCOS management. This is animal evidence only; no human trial data are available for reproductive applications.

6. Body Systems and Health Areas of Association

• Endocrine / Metabolic System: Glycemic control in type 2 diabetes and pre-diabetes; insulin sensitization; lipid modulation.
• Gastrointestinal System: Traditional use as a stomachic, laxative, and anthelmintic; antiulcer activity in preclinical models.
• Immune and Inflammatory System: Anti-inflammatory effects in macrophage models; immunomodulatory activity noted in reviews.
• Oncology: Preclinical in vitro evidence of anticancer activity against breast, liver, colon, head and neck, and other cancer cell lines.
• Infectious Disease / Antiviral: In vitro inhibition of HIV, HSV, and other viruses via MAP30 and momorcharin RIPs.
• Reproductive System: Antifertility and hormonal effects documented in animal studies; traditional use as emmenagogue and for dysmenorrhea.
• Cardiovascular System: Preclinical evidence of cardioprotective and anti-inflammatory effects; a case report of atrial fibrillation associated with ingestion.
• Oxidative Stress / Antioxidant: Multiple in vitro assays document radical scavenging activity.

7. Dosage Forms and Doses Reported in Studies

A wide range of preparations and dosages appear across the published literature. Capsules were the dosage form employed in six studies, while tablets were used in others. Doses in intervention studies ranged from 0.6 g/day to 6 g/day, with some studies having two different intervention dose arms (1 g/day and 1.5 g/day) and a placebo arm.

• Fresh fruit juice: 100 ml bitter melon juice containing 140 g of bitter melon pulp was used in one randomized trial assessing postprandial glucose response.
• Dried fruit powder (capsule): Active arms in one escalating-dose clinical trial were administered capsules containing a total of 500 mg, 1,000 mg, or 1,500 mg of Momordica charantia freeze-dried powder.
• Standardized extract capsule: 500 mg capsules, each containing 200 mg Momordica extract (standardized to 2.5% bitter principle) and 300 mg dried fruit powder, were used in one study design.
• Whole fruit powder (wild bitter gourd): Dried wild bitter gourd powder was filled into capsules at 480 mg each in one metabolic syndrome supplementation trial.
• Tablet (1 g or 1.5 g/day): A parallel randomized controlled trial evaluated 75 uncomplicated type 2 diabetes mellitus patients; Group A received 1 g Momordica charantia tablets and Group B received 1.5 g with oral anti-diabetic agents.
• Powder supplement (prediabetes): One human intervention for prediabetes used a bitter gourd supplement at 2.5 g powder.

Momordica charantia has been shown to be safe in humans at a dose of 20 mg/kg body weight. It has not been shown to be associated with nephrotoxicity, hepatotoxicity, or any adverse influence on food intake, growth, organ weights, or hematological parameters in studies assessing these outcomes at that dose level.

8. Safety Considerations and Drug Interactions

Documented Adverse Effects

Reported adverse effects of bitter melon include hypoglycemic coma and convulsions in children, reduced fertility in mice, a favism-like syndrome, increases in gamma-glutamyltransferase and alkaline phosphatase levels in animals, and headaches.

The fruits and seeds have demonstrated greater toxicity than the leaves or aerial parts of the plant.

Cardiovascular

A case report documented atrial fibrillation in association with bitter melon ingestion. Momordica charantia contains biologically active chemicals that include glycosides, saponins, alkaloids, fixed oils, triterpenes, proteins, and steroids, several of which have been associated with cardiac effects in preclinical models.

Reproductive and Pregnancy Safety

Uterine bleeding in pregnant rats and rabbits was induced with 6 ml/kg fresh fruit juice. Water extract of Momordica charantia is teratogenic in Sprague Dawley rats and should be used with caution. An investigation into the potential estrogenic effects by testing six isolated triterpenoids in an estradiol transactivation assay found that four of the tested compounds showed partial agonistic and/or antagonistic activity via α- and β-estrogen receptors. Pregnancy and use in women attempting conception represent areas of particular documented preclinical concern.

Developmental Toxicity

A study investigated the effect of M. charantia fruit and seed extracts on developmental toxicity in zebrafish embryos. A crude seed extract was lethal with LD50 values of 50 μg/ml, whereas the fruit extract did not result in any lethality up to 200 μg/ml. However, at a concentration of 50 μg/ml, cardiac toxicity for the embryo was observed, which was also much more pronounced for the seed extract (5 μg/ml).

Male Reproductive Toxicity

High-dose M. charantia seed extracts caused infertility in male rats. The interruption in fertility was probably attributed to direct toxicity to seminiferous tubules, epididymis, and lowered testosterone levels which might impact on sperm parameters.

Drug Interactions

There may be an element of drug interaction between M. charantia and commercially available anti-diabetic glucose-lowering drugs, but further experiments are required to determine the kind of interaction which may occur between a commercially available hypoglycemic drug and M. charantia or its hypoglycemic extract.

Medscape's drug interaction database notes that bitter melon increases the effects of acarbose by pharmacodynamic synergism, requiring caution/monitoring due to risk of hypoglycemia. Similar pharmacodynamic synergism is flagged for glimepiride, glipizide, glyburide, and insulin aspart, all posing risk of clinically significant hypoglycemia.

Human Study Safety Data

Studies on the toxicity in humans did not result in serious adverse effects at typical supplementation doses. Momordica treatment was not associated with a notable change in ALT, AST, and creatinine levels compared to placebo in the pooled meta-analysis of RCTs, suggesting absence of hepatotoxic or nephrotoxic signals at doses and durations studied. Nonetheless, both in vitro and in vivo studies have also demonstrated that M. charantia may exert toxic or adverse effects under different conditions.

References

• PubMed: Chemical constituents of Momordica charantia L.
• PMC: Recent Advances in Momordica charantia: Functional Components and Biological Activities
• PubMed: Antioxidant constituents from the stems and fruits of Momordica charantia
• PubMed: Momordica charantia constituents and antidiabetic screening of the isolated major compounds
• PMC: Momordica charantia, a Nutraceutical Approach for Inflammatory Related Diseases
• PMC: Momordica charantia L.—Diabetes-Related Bioactivities, Quality Control, and Safety Considerations
• PubMed: Pharmacological actions and potential uses of Momordica charantia: a review
• PMC: Safety and efficacy of Momordica charantia Linnaeus in pre-diabetes and type 2 diabetes mellitus patients: a systematic review and meta-analysis protocol
• PMC: The metabolic effect of Momordica charantia cannot be determined based on the available clinical evidence: a systematic review and meta-analysis of randomized clinical trials
• PubMed: Effects of Momordica charantia L. supplementation on glycemic control and lipid profile in type 2 diabetes mellitus patients: A systematic review and meta-analysis of randomized controlled trials
• bioRxiv: The efficacy and safety of Momordica charantia L. in animal models of type 2 diabetes mellitus; A systematic review and meta-analysis
• PMC: Medicinal Chemistry of the Anti-Diabetic Effects of Momordica Charantia: Active Constituents and Modes of Actions
• PMC: A case of atrial fibrillation due to Momordica charantia (bitter melon)
• PubMed: Bitter melon (Momordica charantia): a review of efficacy and safety
• PMC: Reproductive toxicity of Momordica charantia ethanol seed extracts in male rats
• PMC: Bitter gourd (Momordica charantia) possess developmental toxicity as revealed by screening the seeds and fruit extracts in zebrafish embryos
• PMC: Oral administration of leaf extracts of Momordica charantia affect reproductive hormones of adult female Wistar rats
• PubMed: Ribosome inactivating proteins (RIPs) from Momordica charantia for anti viral therapy
• PMC: A Novel Method for Simultaneous Production of Two Ribosome-Inactivating Proteins, α-MMC and MAP30, from Momordica charantia L.
• PMC: Cucurbitane Triterpenoid from Momordica charantia Induces Apoptosis and Autophagy in Breast Cancer Cells, in Part, through Peroxisome Proliferator-Activated Receptor γ Activation
• PMC: Antioxidants profile of Momordica charantia fruit extract analyzed using LC-MS-QTOF-based metabolomics
• PMC: Antiviral Potential of Momordica charantia: From Traditional Use to Modern Implications
• PMC: Anti-Infective Activity of Momordica charantia Extract with Molecular Docking of Its Triterpenoid Glycosides
• PMC: Gastroprotective Effect of Polypeptide-K Isolated from Momordica charantia's Seeds on Multiple Experimental Gastric Ulcer Models in Rats
• PMC: Momordica charantia (bitter melon) efficacy and safety on glucose metabolism in Korean prediabetes participants: a 12-week, randomized clinical study
• PMC: Effects of Momordica charantia L. supplementation on glycemic control and lipid profile in type 2 diabetes mellitus patients: A systematic review and meta-analysis of randomized controlled trials
• PMC: Wild bitter gourd improves metabolic syndrome: A preliminary dietary supplementation trial
• PMC: Therapeutic Potential of Momordicine I from Momordica charantia: Cardiovascular Benefits and Mechanisms
• PMC: Natural Compound 3β,7β,25-trihydroxycucurbita-5,23(E)-dien-19-al from Momordica charantia Acts as PPARγ Ligand
• PMC: Teratogenic Effect of the Water Extract of Bitter Gourd (Momordica Charantia) on Sprague Dawley Rats
• PMC: Molecular Docking and In Silico Predictive Analysis of Potential Herb-Drug Interactions Between Momordica charantia and Miglitol
• Medscape: Bitter Melon Drug Interactions and Dosing Reference
• ScienceDirect: Bitter gourd (Momordica charantia L.) supplementation for twelve weeks improves biomarkers of glucose homeostasis in a prediabetic population
• PMC: Therapeutic Investigation of Standardized Aqueous Methanolic Extract of Bitter Melon for Its Potential against Polycystic Ovarian Syndrome